University of Bristol recognised in second Life Sciences Sector Deal
12 December 2018
Life sciences is a sector that operates at the cutting-edge of technological developments. The second Life Sciences Sector Deal was announced on 7 December and the Great West region, including the University of Bristol, was recognised in the report for its flourishing life science industry.
The recognition was due to its collaboration between more established technology and digital businesses and builds on the government’s Life Sciences Industrial Strategy published in December last year, which recognised the importance of regional clusters and followed intense collaboration between life sciences organisations and the GW4 Alliance and GW4's regional strengths such as convergence with AI, high performance computing, quantum technologies and world-leading academic expertise.
The report showcases examples from the University including two spin-out companies. The first is KWS BioTest Ltd, a leading contract research organisation specialising in immunology oncology discovery testing services. The second is Ziylo Ltd, a specialist chemistry company which could transform the treatment of diabetes improving the lives of millions of people around the world. Novo Nordisk acquired Ziylo Ltd in staged acquisition with a potential deal value that could exceed £640 million, one of the largest in the sector during the period since the Life Science Strategy was launched.
Jeremy Tavare, Dean of Faculty of Life Sciences at University of Bristol, said: "The second Life Sciences Sector Deal is key for our research to achieve health and economic impacts. Importantly Bristol’s research and translation portfolio is very well positioned to benefit from the Deal and to integrate across disciplines to yield new globally competitive business opportunities”.
Building links between academia and business
The Elizabeth Blackwell Institute provide support to establish and sustain strategic partnerships with business to both advance science and deliver benefits to society. We represent diverse research at the University of Bristol, which places emphasis on excellence and impact.
We support key health groups at the University of Bristol such as the MRC Integrative Epidemiology Unit (MRC-IEU) and researchers in Bristol Neuroscience and SPHERE by developing partnerships with industry and healthcare partners. Our work is aligned with the University of Bristol Strategy, which was launched in 2016.
The deal announced a £1.3 billion industry-government investment in the UK economy and a new partnership driving early disease detection, with global biopharmaceutical company UCB investing around £1 billion in research and development, including in a new state-of-the-art facility. Places continues to be one of five key commitments within the deal, which this time round has a strong focus on technology and digital innovation.
Read the full story on the Life Sciences Sector Deal.
Find out more about links between our research community and partners in the business sector.